Guangxi Liuzhou Pharmaceutical Co., Ltd. Provides Preliminary Earnings Guidance for the Year 2019
January 09, 2020
Share
Guangxi Liuzhou Pharmaceutical Co., Ltd. provided preliminary earnings guidance for the year 2019. for the year, the company predicts that the net profit belonging to shareholders of the listed company in 2019 will be between RMB 680 million and RMB 730 million with an increase of between RMB 151,814,700 and RMB 201,814,700 and an increase of between 28.74% and 38.21% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations). The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will be between RMB 666.3 million and RMB 716.3 million with an increase of between RMB 137,793,500 and RMB 187,793,500 and an increase of between 26.07% and 35.53% compared with the same period of the year before (based on the disclosed statistics according to relevant regulations).
Guangxi LiuYao Group Co Ltd, formerly Guangxi Liuzhou Pharmaceutical Co Ltd, is a China-based company mainly engaged in the sales of pharmaceuticals. The Company is mainly engaged in three businesses. The pharmaceutical wholesale business mainly distributes pharmaceutical products to medical and health institutions at all levels, pharmaceutical distribution enterprises and chain pharmacies. The pharmaceutical retail business provides sales and health services of various pharmaceutical products, medical devices and other pharmaceutical products to individual consumers through terminal pharmacies. The pharmaceutical industry business is mainly engaged in the production and processing of traditional Chinese medicine pieces and traditional Chinese medicine formula granules. The Company is also engaged in supply chain value-added services, pharmaceutical Internet services, terminal health services and others.
GUANGXI LIUYAO GROUP CO., LTD 
